Evaluation of the expression of EGFL7 in glioblastoma and its correlation with clinicopathological data

• Grant number: 18/20737-1
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2018
• End date: November 30, 2019
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Lucas Tadeu Bidinotto
• Grantee: Bruno Henrique Bressan da Costa
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil

Abstract

Gliomas are the most frequent and malignant brain tumors among the central nervous system neoplasms. Among glial types, glioblastomas (GBMs) are incurable, with an average survival of approximately 13 months, and less than 2% of patients reach 5 years after treatment. The low success rate in these tumors is due in part to the low understanding of their molecular basis. In 2016 our research group found chromosomal loss in regions of the short arm of the chromosome in a high percentage of these patients and recently we found high expression of EGFL7 related to worse survival in patients diagnosed with pilocytic astrocytoma. Therefore, the present project aims to evaluate the expression of EGFL7 in glioblastomas correlating with clinicopathological data. Initially, in silico analyzes will be performed with GBM data from The Cancer Genome Atlas (TCGA) using specific packages in the R software. The methylation pattern, copy number and EGFL7 expression will be correlated in an integrated analysis. Then the expression of this gene will be correlated with the tumor subtype (classical, mesenchymal, proneural, neural and G-CIMP +) and survival. In addition, the expression of this gene will be correlated with the expression of the other genes evaluated in the microarray of expression of the TCGA, in the objective of finding coexpressed genes. Finally, the protein expression of EGFL7 will be assessed by immunohistochemistry in a tissue microarray of glioblastoma, with 60 patients, in duplicates. The expression pattern will be correlated with the clinicopathological data of the patients. Finally, the expression profile of EGFL7 will be evaluated in 5 commercial cell lines of glioblastoma via western blot.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DA COSTA, BRUNO HENRIQUE BRESSAN; BECKER, ALINE PAIXAO; NEDER, LUCIANO; GONCALVES, PAOLA GYULIANE; DE OLIVEIRA, CRISTIANE; POLVERINI, ALLAN DIAS; CLARA, CARLOS AFONSO; TEIXEIRA, GUSTAVO RAMOS; REIS, RUI MANUEL; BIDINOTTO, LUCAS TADEU. EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome. JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, v. N/A, p. 10-pg., 2022-06-15. (18/20737-1, 17/09749-5, 16/21727-4)